Jump to start of content

Technical Support for those taking the Knowledge Check-In at home/in office Expand/Collapse the ABIM alert.

Technical assistance on the day of your Knowledge Check-In assessment is available by chatting with a Pearson VUE agent. We are here to help! You may also call 800-606-0259 to reach an ABIM Customer Relationship Advocate, in the event you are unable to connect to a Pearson VUE agent.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Medical Oncology Board

Expand All | Collapse All

Robert D. Siegel, MD, Chair

Robert D. Siegel, MDDr. Siegel, a board-certified internist, hematologist and medical oncologist, is the Oncology Program Director for the Bon Secours St. Francis Health System in Greenville, South Carolina. Prior to his appointment to program leadership at St. Francis, Dr. Siegel had been a community-based oncologist with particular interest in quality improvement initiatives and cancer care delivery research.

Dr. Siegel has served the American Board of Internal Medicine (ABIM) as a member of the Medical Oncology Exam Writing Committee and is currently chair of its Medical Oncology Board. Additionally, he is a member of the ABIM Board of Directors and the ABIM Council. He has previously served as the co-Chair of the Quality of Care Subcommittee for the National Cancer Institute's Community Cancer Centers Program and is currently on the Executive Committee of the Upstate Carolina NCI Community Oncology Research program (NCORP).

Dr. Siegel earned his medical degree at the Columbia University College of Physicians and Surgeons in New York. He completed his internship and residency training at the Barnes Hospital/Washington University School of Medicine in St. Louis and fellowship training in medical oncology and hematology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston.

As of February 2020, Dr. Siegel reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Bon Secours St. Francis Hospital, from the following companies:

  • Bristol-Myers Squibb, for a lung cancer clinical trial, kidney cancer clinical trial, and for a non-Hodgkin lymphoma clinical trial.
  • Cancer Insight, for a melanoma clinical trial.
  • Merck, for clinical trials for head and neck carcinoma, breast carcinoma, lymphoma, and stomach cancer clinical trials.
  • Mirati Therapeutics, for a clinical trial for solid tumors.
  • Biodesix, for an observational study assessing the clinical effectiveness of validating immunotherapy tests in subject with non-small cell lung cancer.
  • CerRX Inc., for a Phase II trial of intravenous fenretinide emulsion for patients with relapsed/refractory peripheral T-cell lymphomas.
  • Boston Biomedical, for a Phase II trial of metastatic pancreatic ductal adenocarcinoma.
  • GRAIL, Inc., for a trial of use deep sequencing of circulating cell-free nucleic acids to develop assays to detect cancer early in blood.
  • Pharmatech, for a trial of the treatment of cutaneous T-cell lymphoma.
  • Altor Bioscience, for two studies on advanced and metastatic non-small lung cancer.
  • AstraZeneca, for a study of durvalumab +tremelimumab combination therapy or durvalumab monotherapy in advanced solid malignancies.
  • Calithera Biosciences, for a study of advanced or metastatic renal cell carcinoma.
  • Galera Therapeutics, for a study of locally advanced, non-metastatic squamous cell carcinoma of the oral cavity or oropharynx, and for a study of incidence of esophagitis in in patients receiving chemoradiotherapy for lung cancer.
  • Apollomics, for a study of non-small cell lung cancer with c-Met EXON 14 skip mutations and c-Met dysregulation advanced solid tumors.
  • Exact Science, for blood sample collection to evaluate biomarkers in subjects with untreated hematologic malignancies.
  • Strata Oncology, for a study of molecular profiling of biospecimens from cancer patients to assist in screening for clinical trial enrollment.
  • Arcus, for a Phase 1b study to evaluate the safety and clinical activity of AB122 in biomarker-selected participants with advanced solid tumors.
  • Summit, for a study on patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations of EGFR gene amplification.

Dr. Siegel serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society for Clinical Oncology, Past Chair of Quality Oncology Practice Initiative Certification Oversight Committee, Chair Elect Quality Oncology Practice Initiative Steering Group, Quality Care Committee Member, and International Quality Task Force Member, receiving reimbursement for travel expenses.
  • Guardian Research Network, Board of Directors, without compensation.
  • Southeastern Health Partners, Board of Directors, without compensation.

Linda S. Ahn, MSN

Linda S. Ahn, MSNMs. Ahn is a Clinical Trials Nurse Practitioner in the Thoracic Medicine Program at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. She has worked at MSKCC for 14 years, starting as a new graduate registered nurse on the Genitourinary/Head &Neck inpatient service. She then worked as an office practice nurse in the Gastrointestinal/Sarcoma program in the outpatient setting.

After receiving a master's degree in Adult Primary Care in 2008, she took a position as a Clinical Trials Nurse Practitioner in the Sarcoma Program. She briefly left MSKCC for a position as Nurse Practitioner overseeing sarcoma patients in the outpatient setting at Mount Sinai Hospital in New York City.

Ms. Ahn earned her bachelor's degree in nursing from SUNY Binghamton and master's degree in adult primary care from New York University.

As of July 2019, Ms. Ahn reported no external relationships.

Tareq Al Baghdadi, MD

Dr. Al Baghdadi is a practicing board certified hematologist and medical oncologist at IHA Hematology and Oncology Associates in Ypsilanti, Michigan. He is also affiliated with St. Joseph Mercy Ann Arbor in Ann Arbor, Michigan.

Dr. Al Baghdadi has clinical interest in hematology, and breast and urologic cancers. He is a member of the American Board of Internal Medicine Medical Oncology Board, the National Cancer Institute Leukemia Steering Committee and the National Myelodysplastic Syndromes Study Steering Committee. Dr. Al Baghdadi also serves as co-Principal Investigator for the Michigan Cancer Research Consortium and is a member of the Alliance Community Oncology Leadership Committee.

Dr. Al Baghdadi is a member of the American Society for Clinical OOncology (ASCO) Targeted Agent and Profiling Utilization Registry Molecular Tumor Board, and also a member of the Alliance Genitourinary Oncology committee and has completed ASCO leadership training program.

He received his medical degree from the University of Damascus Faculty of Medicine in Syria. He completed residency training at William Beaumont Hospital in Royal Oak, Michigan, and fellowship training in hematology and oncology at Indiana University in Indianapolis, Indiana.

As of July 2019, Dr. Al Baghdadi reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Bristol-Myers Squibb
  • Cardinal Health
  • Celgene
  • Heron Therapeutics

William J. Gradishar, MD

Dr. Gradishar is Deputy Director for the Clinical Network of the Lurie Cancer Center and oversees the coordination of clinical cancer services within Lurie Cancer Center’s affiliated network, working closely with the medical director for Oncology Services in the different regions of Northwestern Medicine. Dr. Gradishar is chief of the Division of Hematology and Oncology in the Department of Medicine and Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine. He is also director of Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials of new therapeutic approaches for breast cancer.

Dr. Gradishar has served as chair of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium, a nationally recognized, four-day meeting for the practicing clinician, since its inception in 1998. His research focuses on the development of adjuvant therapies and novel therapeutics for the treatment of breast cancer.

A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology (ASCO), Dr. Dr. Gradishar is also a member of the American Association for Cancer Research and the American Federation for Clinical Research. He has held numerous leadership positions in ASCO, been a member of numerous study sections for funding agencies including the Department of Defense, National Institutes of Health, Komen Foundation and American Cancer Society. He has served as a consultant to the FDA Oncology Drug Advisory Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group. Gradishar is chair of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and a member of the Breast Cancer Prevention Panel. He was recently appointed chair of the Breast Cancer Working Group for the Moonshot 2020 Initiative, which will spearhead the development of novel therapeutics for the treatment of breast cancer.

Dr. Gradishar is a member of the editorial boards of the Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Cancer, European Journal of Medical Oncology, Oncology and editor-in-chief of NEJM Journal Watch: Oncology and Hematology.

Dr. Gradishar received his medical degree from the University of Illinois, Chicago. He completed his residency at Michael Reese Medical Center and his fellowship at University of Chicago Hospitals.

As of November 2019, Dr. Gradishar reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Genentech
  • Seattle Genetics

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • AbbVie, receiving honoraria.
  • CVS, receiving honoraria.
  • AstraZeneca, receiving honoraria and reimbursement for travel expenses.
  • Merck, receiving honoraria.
  • Eli Lilly & Company, receiving honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with honoraria:

  • AbbVie

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Genentech, receiving honoraria reimbursement for travel expenses.
  • Pfizer, receiving honoraria reimbursement for travel expenses.
  • Research to Practice, receiving honoraria.

Ann S. LaCasce, MD

Ann S. LaCasce, MD Since 2003, Dr. LaCasce has been a member of the Lymphoma Program at Dana-Farber where she performs clinical research. She has a longstanding interest in medical education, and in 2011, she assumed the role of Program Director of the Dana-Farber/Partners Cancer Care Fellowship which is the largest hematology/oncology training program in the country. She is an Associate Professor of Medicine at Harvard Medical School and is board certified in medical oncology.

She serves as a member of the American Board of Internal Medicine Medical Oncology Board; and she also serves as a member of the American Society of Hematology Committee on Training and is chair, American Society of Clinical Oncology Training Program Committee. In addition, she is a member of the National Comprehensive Cancer Network's Lymphoma Guideline Panel and serves on the Lymphoma Research Foundation's Scientific Advisory Board.

Dr. LaCasce graduated from Bowdoin College with a degree in bBiochemistry and earned her medical degree from Tufts University School of Medicine. She completed training in internal medicine at Brigham and Women's Hospital in Boston, where she later served as a Chief Medical Resident. After her fellowship in medical oncology at Dana-Farber/Partners Cancer Care where she pursued formal training in clinical investigation, earningshe earned a mMaster in mMedical sScience from Harvard/MMassachusetts Institute of Technology Division of Health Sciences and Technology.

As of July 2019, Dr. LaCasce reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with and honoraria:

  • Bristol-Myers Squibb.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

  • Seattle Genetics.

Industry-supported continuing medical education supported by the following company, with compensation for travel expenses and honoraria:

  • Research to Practice, for a lymphoma panel.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.

Dr. LaCasce serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, Oncology Training Program Committee Member, receiving reimbursement for travel expenses.
  • American Society of Hematology, Training Committee Member, receiving reimbursement for travel expenses.
  • Lymphoma Research Foundation, Scientific Advisory Board Member, receiving reimbursement for travel expenses.

Suresh G. Nair, MD

Suresh G. Nair, MDDr. Nair is the Physician-in-Chief of the Lehigh Valley Cancer Institute and leads the health network’s academic programs. Dr. Nair is the Medical Director of the Lehigh Valley Cancer Institute membership in the Memorial Sloan Kettering Cancer Center Alliance and has practiced oncology in the community setting for 30 years. He is the initial holder of The Auxiliary of Lehigh Valley Hospital Endowed Chair in Cancer.

With clinical expertise in melanoma, kidney cancer and immunotherapy, Dr. Nair’s focus is to provide the highest-quality cancer care, including standard and research treatments. He leads a variety of clinical trials at Lehigh Valley Health Network (LVHN) to provide leading-edge options to patients. Dr. Nair started the hematology/oncology fellowship at LVHN and served as the initial program director, and remains on core faculty. He is a member of the American Board of Internal Medicine Medical Oncology Board.

Dr. Nair has been a site principal investigator in the National Cancer Institute (NCI) Cooperative Group Program for over 25 years and was the first Chair of the NCI Early Phase Central IRB. He has been a site principal investigator of over 40 T-cell checkpoint inhibitor trials at the Lehigh Valley Cancer Institute.

Dr. Nair received his medical degree from Jefferson Medical College. He completed his residency at Geisinger Medical Center and his fellowship at the University of Pittsburgh.

As of May 2018, Dr. Nair reported the following external relationships:

Funding for clinical trial support accrual, paid to Lehigh Valley Health Network, from the following companies:

  • Bristol-Myers Squibb, for Phase II and Phase III Immuno-Oncology clinical trials.
  • Merck, for a Phase III clinical trial for treatment of metastatic renal carcinoma.
  • DNAtrix, for a Phase II clinical trial for treatment of glioblastoma.

Olatoyosi Odenike, MD

Olatoyosi Odenike, MDDr. Odenike, a board-certified medical oncologist, is an Associate Professor of Medicine at the University of Chicago. Dr. Odenike's clinical research and medical practice is focused on myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes and chronic myeloproliferative neoplasms. She has a particular interest in new drug development in these diseases.

Prior to joining the faculty at the University of Chicago, Dr. Odenike worked as an Attending Physician at Roseland Community hospital, a medically underserved community on the South Side of Chicago.

Dr. Odenike currently serves as member of the American Board of Internal Medicine Medical Oncology Board Exam Committee and Medical Oncology Specialty Board. She is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. Additionally, she has served on various professional committees including American Society of Clinical Oncology (ASCO) Scientific Program Committee for which she also served as a Track Leader, ASCO Cancer Communications Committee and the Best of ASCO Program Committee, and she has served as Chair of Educational Programs for both ASCO and the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program. She has served in various editorial capacities and review committees including the Conquer Cancer Foundation of ASCO grant review committee, ASCO International Innovation Grant review subcommittee and currently serves as Vice Chair of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike has served on the Molecular and Cellular Hematology National Institutes of Health Study Section. She is the recipient of an ASCO Career Development Award and is listed in Best Doctors in America as well as Castle Connolly's Top Doctors.

Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University of Illinois and her fellowship training in hematology/oncology at the University of Chicago.

As of May 2019, Dr. Odenike reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • AbbVie
  • Agios
  • Astex
  • Celgene
  • CTI Biopharma
  • Janssen
  • Incyte
  • Millennium
  • NS-Pharma
  • Oncotherapy Sciences
  • Plexxicon

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • AbbVie, for serving on an advisory board regarding the role of venetoclax in adult acute myeloid leukemia, receiving honoraria.
  • Celgene, for serving on advisory boards on JAK inhibitors in myelofibrosis and luspatercept in myelodysplastic syndrome, receiving reimbursement for travel expenses and honoraria.

Dr. Odenike serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Alliance Cooperative Group, Leukemia Core Committee Member, without compensation.
  • American Society of Clinical Oncology, International Innovation Grant Review Subcommittee Member.
  • National Institutes for Health, Molecular and Cellular Hematology Standing Committee member, receiving reimbursement for travel expenses and honoraria.
  • American Society of Hematology: Education Program, receiving honoraria.
  • The France foundation: Educational Symposium on adult acute myeloid leukemia and myelodysplastic syndrome matters, receiving reimbursement for travel expenses and honoraria.

Emily Taylor

Emily TaylorMs. Taylor was diagnosed with Stage IV lung cancer in 2012 at age 28, with no known genomic markers. After undergoing chemotherapy, radiation and surgery to remove her entire right lung, pleura, and parts of her diaphragm, pericardium, and mediastinum, and she is thrilled to have NED (no evidence of disease) for the past 6+ years.

As a young, healthy athlete and never smoker, she is working to change the public perception of who gets lung cancer, to achieve better funding, better research, and better outcomes for patients. She volunteers as a Spokesperson/Patient Advocate for the Go2 Foundation for Lung Cancer (formerly Addario Lung Cancer Foundation and Lung Cancer Alliance), and also serve on the Speakers Bureau for the City of Hope, sharing her story at conferences and fundraising events. She also serves as a member of the American Board of Internal Medicine Medical Oncology Board, and maintains a blog, sharing her progress from diagnosis to present, which connects her with patients all over the world.

In her spare time, she enjoys spending time with her husband and their twin daughters, who were born from the embryos they preserved before starting treatment and were carried by her dear friend and high school track coach.

As of May 2020, Ms. Taylor reported the following external relationships:

Ms. Taylor serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • GO2 Foundation for Lung Cancer National Ambassador Council Member, without compensation.